Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2051)
•••
Post by Oden6570on Apr 13, 2024 8:23am
239 Views
Post# 35987279

TLD-1433, prepared by McFarland and co-workers,

TLD-1433, prepared by McFarland and co-workers,Photodynamic therapy (PDT) is an approved anticancer strategy that provides spatial and temporal control over drug activation and has attracted great attention in anticancer drug development to combat multidrug resistance, showing fewer side effects and higher selectivity than conventional therapies. (5−14) Ruthenium complexes, with their rich photophysical and photochemical characteristics, have long been at the forefront of metal-based photosensitizers (PSs). (15−19) The photodynamic therapy-based Ru(II) therapeutic, TLD-1433, prepared by McFarland and co-workers, has entered clinical trials and is currently in phase II for nonmuscle invasive cancer (NMIBC). (20) Iridium complexes offer the advantages of long phosphorescence lifetime, significant photostability, and multiple photosensitization mechanisms. (21−26)
Novel 2-(5-Arylthiophen-2-yl)-benzoazole Cyclometalated Iridium(III) dppz Complexes Exhibit Selective Phototoxicity in Cancer Cells by Lysosomal Damage and Oncosis | Journal of Medicinal Chemistry (acs.org)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities